Human medicines European public assessment report (EPAR): Lojuxta, lomitapide, Date of authorisation: 31/07/2013, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 32, Status: Authorised

Summary of opinion: Stelara, 25/06/2026 Positive

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised

European Medicines Regulatory Network (EMRN) workshop on geographic atrophy endpoints, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 29 April 2026

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

EMEA-002451-PIP02-21

Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 6, Status: Authorised

List of medicinal products under additional monitoring